

- Epilepsy (*Cont.*):
 pregnancy and, 49, 2559
 psychiatric disorders associated with, 2558
 psychosocial issues in, 2558
 refractory, 2556–2557
 in schistosomiasis, 1427
 syndromes, **2544**
 age-related, 2545–2547
 genetic, 2545t
 juvenile myoclonic epilepsy, 2544
 Lennox-Gastaut syndrome, 2544
 mesial temporal lobe epilepsy, 2544, 2546f, 2546t
 treatment of, **2551**
 antiepileptic drug therapy. *See* Antiepileptic drugs (AEDs); *specific drugs*
 avoidance of precipitating factors in, 2551–2552
 management of underlying conditions, 2551
 in refractory disease, 2556–2557
 surgical, 2556–2557
 in women, 2559
- Epileptiform activity, 442e-1, 2550
- Epileptogenesis, 2548
- Epinephrine
 for anaphylaxis, 2117, 2749
 for brittle asthma, 1680
 for cardiac arrest, 1769, 1769f
 in cardiovascular regulation, 1613
 for drug-induced urticaria/angioedema, 381
 drug interactions of, 381
 in hypoglycemia, 2431t
 in local anesthetics, 242
 for parainfluenza virus infection, 1208
 as premedication for antivenom, 2737
 reference values for, 2759t
 for scambroid poisoning, 2744
 in shock, 1745
 in vascular smooth-muscle cells, 265e-4
- Epinephrine challenge test, 423
- Epirretinal membrane, 206
- Epirubicin, 103e-10t, 124e-4, 535
- Episcleritis, 200, 1958
- Episodic ataxia, 444e-2t, 451e-3t, 2629
- Epistaxis, 440
- Epistaxis
 approach to the patient, 403
 vs. hemoptysis, 245
 in nasopharyngeal cancer, 503
 in Osler-Weber-Rendu disease, 732
 in von Willebrand disease, 730
- Epistemic cells, 453t
- Epithelial cells/epithelium
 in adaptive immunity, 372e-7t
 airway, in asthma, 1673, 1674
 gastric, 1911–1914
 high-resistance, 332e-9
 intestinal, 86e-7, 1933
 pathogen encounters with, 145e-4–5, 145e-4f
 permeability of, 332e-3, 372e-23, 372e-25f
- Epithelial-mesenchymal transition, 102e-10, 102e-11f
- Epithelioid hemangioendothelioma, 552
- Epitopes, 377e-2
- Eplerenone
 adverse effects of, 64e-2
 drug interactions of, 205e-3
 for heart failure, 1511, 1512t
 for hypertension, 1623, 1624t, 1625
 for mineralocorticoid excess, 2319
- Epley maneuver, 150, 150f
- EPM2A* gene mutations, 2545t
- EPOCH regimen, 135e-2
- Epoprostenol, 1659, 1660t, 2164
- Epothilones, 103e-15, 531
- EPP. *See* Erythropoietic protoporphyria (EPP)
- Eprodiasate, 723
- Epsilometer (E-test), 150e-9
- Epsilon wave, 1495
- Epstein-Barr virus (EBV), 145e-2t, 214e-1, 214e-4, 1186–1187
- Epstein-Barr virus (EBV) infections, **1187**
 B-cell lymphoproliferative disease and, 214e-7, 623–624, 922, 1188
 Burkitt's lymphoma and, 101e-7, 477t, 695, 1188, 1375
 cancer and, 477t
 chronic fatigue syndrome and, 1188
 clinical features of, 1186–1187
 complications of, 1188
 diagnosis of, 150e-2, 150e-7, 233, 1188, 1189, 1189f, 1190t
 encephalitis, 894, 895t
 epidemiology of, 1187
 Hodgkin's lymphoma and, 214e-7, 697, 1189
 infectious mononucleosis. *See* Infectious mononucleosis
 lymphadenopathy in, 408
 lymphoid malignancies and, 135e-3, 135e-4, 214e-7, 488, 601, 697, 697t, 1188–1189
 meningitis, 892
 myelitis, 2657
 nasopharyngeal cancer and, 214e-7, 502, 503, 1188–1189
 neuropathy in, 2685
 oral hair leukoplakia, 1188, 1188f
 pathogenesis of, 1187
 pharyngitis, 231
 primary effusion lymphoma and, 135e-2
 reactivation in hypersensitivity syndrome, 382
 rheumatoid arthritis and, 2140
 skin manifestation of, 362, 362t
 SLE and, 2126
 systems biology applied to, 87e-3t
 thymoma and, 123e-2
 in transplant recipient
 after HSCT, 920t, 921t, 922–923
 after solid organ transplant, 924t, 925, 926
 treatment of, 926
 treatment of, 1189–1190
 vasculitis, 2193
- Epstein's syndrome, 729
- Eptifibatid
 action of, 746f, 748–749
 adverse effects of, 727t, 749
 discontinuation before lumbar puncture, 443e-1
 dosage of, 749
 genetic variations in response to, 277t, 743t
 indications for, 749
 for myocardial infarction, 1598t
 for PCI, 296e-1
 pharmacology of, 749t
- Epulis (gingival hypertrophy), 46e-2f
- Epulis fissuratum, 46e-2f
- Epworth sleepiness scale, 1721
- Equine antitoxin, for tetanus, 986
- Equine immunoglobulin, hyperimmune, 1328
- Eradication, of disease, 785
- erbB2* gene mutations
 in breast cancer, 101e-3, 524, 528, 531
 tumors associated with, 101e-2t
- ERBB4* gene mutations, 465e-4
- Erb's palsy, 48
- ERCC-6* gene, 94e-4
- ERCC-8* gene, 94e-4
- ERCP. *See* Endoscopic retrograde cholangiopancreatography (ERCP)
- Erectile dysfunction (ED), **326**
 after cystectomy, 577
 after prostatectomy, 583
 after radiation therapy, 583, 623
 alcohol use and, 2725
 approach to the patient, 327–328, 327f
 autonomic dysfunction and, 2639
 cocaine use and, 469e-1
 in diabetes mellitus, 2427
 drug-related, 326–327, 327t
 epidemiology of, 326
 pathophysiology of, 326–327
 prevalence of, 2254t
 screening/testing for, 2254t
 in systemic sclerosis, 2162
 treatment of, 328–330, 329t
- Erection, 324, 325f
- Ergot alkaloids, 473e-3, 473e-8t, 1649
- Ergotamine
 adverse effects of, 2591
 for exertional headache, 2597
 for migraine, 2591, 2592t, 2593t
 overdose/poisoning with, 473e-8t
 for sex headache prevention, 2597
- ERG* overexpression, 680, 680t
- Erlotinib
 action and targets of, 102e-3, 102e-5t, 103e-16, 103e-16f, 103e-17t, 103e-19
 adverse effects of, 103e-17t, 103e-26, 380, 380f, 1797
 for cholangiocarcinoma, 553
 for head and neck cancer, 505
 for hepatocellular carcinoma, 551
 for lung cancer, 102e-3, 102e-5t, 103e-16, 103e-19, 520t, 521, 521t
 for pancreatic cancer, 102e-5t, 557, 557t
 resistance to, 103e-23
- ermB* gene, 807
- Erosio interdigitalis blastomycetica, 1343
- Ertapenem
 for anaerobic bacterial infections, 1101
 for community-acquired pneumonia, 808t
 for health care-associated pneumonia, 812t
 indications for, 940t, 941
 in pregnancy and lactation, 937t
 resistance to, 933, 940t
- Erucism, 2750
- Erve virus, 1308t
- Erysipelas
 etiology of, 828t, 967
 pathophysiology of, 827f, 830
 skin manifestations of, 25e-4f, 76e-8f, 364t, 830, 967, 967f
 treatment of, 830, 965t, 967
- Erysipelothrix rhusiopathiae*, cellulitis, 830
- Erythema, 386
- Erythema annulare centrifugum, 355, 356t
- Erythema elevatum diutinum, 364t, 367
- Erythema gyratum repens, 355, 356f
- Erythema induratum, 366
- Erythema infectiosum (fifth disease)
 clinical features of, 128t, 1196
 diagnosis of, 1196t
 epidemiology of, 128t
 etiology of, 128t
 skin manifestations of
 buttocks, 25e-1f, 76e-8f
 facial, 25e-1f, 1196f
 progression of, 127, 128t, 362, 362t
- Erythema marginatum, 129t, 134, 356, 2152.
See also Rheumatic fever
- Erythema migrans. *See also* Lyme borreliosis (Lyme disease)
 clinical features of, 25e-2f, 76e-9f, 134, 355–356, 1150f
 evolution of, 1150
- Erythema multiforme
 in cancer patient, 487
 classification of, 361
 clinical features of, 340, 343f, 361, 361t
 differential diagnosis of, 130t
 epidemiology of, 130t
 etiology of, 361
 HSV infection and, 1178, 1182t
 oral manifestations of, 239t
 skin manifestations of, 25e-6f, 76e-14f, 130t, 134
- Erythema nodosum
 clinical features of, 132t, 366
 epidemiology of, 132t
 etiology of, 132t
 in IBD, 1957
 skin manifestations of, 25e-10f, 76e-15f, 132t, 135
- Erythema nodosum leprosum, 1124, 1124f, 1128
- Erythrasma, 343, 981
- Erythroblastosis fetalis, 236
- Erythrocyte sedimentation rate (ESR)
 in fever evaluation, 125
 in giant cell arteritis, 108